Endobronchial Ultrasound Biopsy Market Forecast 2026-2036: Market to Reach USD 1,520 Million by 2036 at 6.3% CAGR

NEWARK, DE | The endobronchial ultrasound biopsy market was valued at USD 0.77 billion in 2025. Demand for endobronchial ultrasound biopsy systems and dedicated consumables is projected to expand from USD 0.82 billion in 2026 to USD 1.52 billion by 2036, reflecting a steady CAGR of 6.3% over the forecast period. This measured growth underscores the increasing role of minimally invasive mediastinal staging in lung cancer diagnostic pathways, where EBUS supports accurate nodal sampling while helping reduce reliance on more invasive surgical approaches.

Read Full Report:https://www.futuremarketinsights.com/reports/endobronchial-ultrasound-biopsy-market

Market snapshot: global market 2026 - 2036

Market size 2026? USD 823.3 million (USD 0.82 billion)
Market size 2036? USD 1,516.7 million (USD 1.52 billion)
CAGR? 6.3%
Leading product segment(s) and shares: EBUS Scopes lead demand with an estimated 33% share in 2026
Leading procedure type and share: Convex-probe (Linear / CP-EBUS) Scopes hold 61.1% share in 2026
Leading end use: Not explicitly quantified by share in source; hospitals (including community, academic/teaching, and large multispecialty networks) remain the primary setting
Key growth regions: Asia Pacific leads incremental volume growth, with China and India showing the highest CAGRs due to expanding tertiary hospital capacity and interventional pulmonology training
Top companies: Olympus Corporation, FUJIFILM Holdings Corporation, GE HealthCare, Siemens Healthineers AG, Koninklijke Philips N.V., Boston Scientific Corporation, Cook Group Incorporated, Medi-Globe Technologies GmbH, ACE Medical Devices Pvt. Ltd., Praxis Medical

Market Momentum (YoY Path)

The endobronchial ultrasound biopsy market exhibits consistent expansion, starting from USD 0.77 billion in 2025 and reaching USD 0.82 billion in 2026. Growth continues steadily toward approximately USD 1.0 billion around 2030-2031, with further acceleration supporting values near USD 1.2 billion by 2033 and culminating at USD 1.52 billion by 2036. Absolute dollar growth of about USD 0.69 billion over the decade reflects guideline-driven increases in staging volumes and broader bronchoscopy programme adoption rather than abrupt spikes.

Why the Market is Growing

Demand for endobronchial ultrasound biopsy continues to rise as lung cancer diagnostic pathways increasingly mandate minimally invasive mediastinal staging, boosting procedure volumes in centres with trained staff and ultrasound platforms. Formalising specimen processing and handling standards improves diagnostic yield and reduces re-biopsies, encouraging investment in repeatable workflows. Ongoing product development focused on workflow efficiency-such as scope designs that streamline pre-procedure setup-facilitates wider adoption across bronchoscopy suites.

Segment Spotlight

Product Type

EBUS Scopes command the leading position with an estimated 33% share in 2026. These devices serve as the foundational asset for ultrasound-guided staging and biopsy, driving recurring demand for EBUS-TBNA needles, sheaths, and related consumables as procedure volumes increase in high-throughput settings.

Procedure Type

Convex-probe (Linear / CP-EBUS) Scopes dominate with a 61.1% share in 2026. This procedure type excels in providing real-time needle guidance for mediastinal and hilar lymph node sampling, aligning closely with staging pathways that require nodal confirmation to guide treatment selection and radiotherapy planning.

End Use

Hospitals-including community hospitals, academic/teaching hospitals, and large multispecialty networks-remain the dominant setting for endobronchial ultrasound biopsy procedures. This reflects the need for specialised bronchoscopy suites, multidisciplinary teams, and reliable infrastructure to support consistent staging and diagnostic workflows in lung cancer care.

Drivers, Opportunities, Trends, Challenges

Drivers

Guideline-driven staging demand reinforces minimally invasive mediastinal sampling in defined clinical scenarios, sustaining procedure volumes. Specimen workflow standards from professional societies raise expectations for sample adequacy and repeatability, supporting investment in standardised kits, training, and dedicated consumables. Asia Pacific capacity build in China and India expands tertiary infrastructure and training, lifting installed base and throughput.

Opportunities

Bundled offerings that combine scopes, processors, consumables, service uptime, and clinical training can reduce outcome variability across sites. Prioritising workflow integration across bronchoscopy, pathology, and oncology teams helps protect sample quality for biomarker testing and multidisciplinary decisions.

Trends

Product development emphasises workflow efficiency, including balloonless scope designs and integrated respiratory endoscopy platforms that tie upgrades to imaging performance and pathway metrics. Specimen handling guidance shifts vendor selection toward service, training, and integration beyond unit price.

Challenges

Procurement decisions balance the clinical value of faster, safer staging against capital budgets for scopes and processors, which compete with other imaging modalities and surgical priorities. Centres lacking stable sedation capacity, pathology turnaround, or trained bronchoscopists face barriers to justifying new EBUS platforms.

Competitive Landscape

Competition in the endobronchial ultrasound biopsy market is moderately concentrated among major platform providers for scopes and processors, while more fragmented in accessories and consumables. Key players focus on imaging performance, service uptime, training support, and sampling reliability. Structural advantages lie with companies controlling both scopes and imaging ecosystems, enabling bundled upgrades, training, and service contracts that influence standardisation across hospital networks.

Subscribe for Year-Round Insights → Stay ahead with quarterly and annual data updates:https://www.futuremarketinsights.com/reports/brochure/rep-gb-26332

Get Access of Report Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-26332

Scope of the Report

Quantitative units: Market value in USD million from USD 823.3 million (2026) to USD 1,516.7 million (2036), at a CAGR of 6.3%
Market definition: Covers EBUS scopes, ultrasound processors/imaging systems, and dedicated biopsy consumables (including EBUS-TBNA needles) for minimally invasive sampling and staging of mediastinal/hilar lymph nodes and related pulmonary diagnostics
Segmentation: Product outlook (EBUS Scopes; EBUS-TBNA Needles & Dedicated Biopsy Consumables; Ultrasound Processors and Imaging Systems; Accessories & Ancillaries); Procedure outlook (Convex-probe (Linear / CP-EBUS) Scopes; Radial-probe (RP-EBUS) Scopes); End-use outlook (Hospitals, Ambulatory Surgical Centers, Specialty Clinics)
Regions: North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Countries: United States, Canada, Mexico, Brazil, Germany, France, United Kingdom, China, India, and 40+ additional countries
Key companies profiled: Olympus Corporation, GE HealthCare, Siemens Healthineers AG, Koninklijke Philips N.V., Boston Scientific Corporation, Cook Group Incorporated, FUJIFILM Holdings Corporation, Medi-Globe Technologies GmbH, ACE Medical Devices Pvt. Ltd., Praxis Medical

FAQ

What is the projected size of the endobronchial ultrasound biopsy market in 2036? The market is forecast to reach USD 1.52 billion (USD 1,516.7 million) by 2036.

What is the expected CAGR for the endobronchial ultrasound biopsy market from 2026 to 2036? The market is projected to grow at a CAGR of 6.3% during the 2026-2036 period.

Which product segment leads demand in 2026? EBUS Scopes are estimated to hold a 33% share in 2026, serving as the core enabling asset for procedures.

Which procedure type holds the largest share in 2026? Convex-probe (Linear / CP-EBUS) Scopes account for 61.1% share in 2026 due to real-time guidance capabilities essential for mediastinal staging.

Which regions show the strongest growth? China (8.5% CAGR) and India (7.9% CAGR) lead, driven by tertiary hospital expansion and training pipelines in Asia Pacific.

Explore More Related Studies Published by FMI Research:

Infant Heart Monitor Market: https://www.futuremarketinsights.com/reports/infant-heart-monitor-market

Dermal Fillers Market: https://www.futuremarketinsights.com/reports/dermal-fillers-market

Automated Cell Culture Systems Market: https://www.futuremarketinsights.com/reports/automated-cell-culture-systems-market

Auto-Injectors Market: https://www.futuremarketinsights.com/reports/auto-injectors-market

GLP-1 Obesity Home Delivery Injectables Market: https://www.futuremarketinsights.com/reports/glp-1-obesity-home-delivery-injectables-market

Why FMI: Decisions that Change Outcomes- https://www.futuremarketinsights.com/why-fmi

Have a specific Requirements and Need Assistant on Report Pricing or Limited Budget please contact us - sales@futuremarketinsights.com

Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-347-918-3531
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

About Future Market Insights (FMI)

Future Market Insights, Inc. (FMI) is an ESOMAR-certified, ISO 9001:2015 market research and consulting organization, trusted by Fortune 500 clients and global enterprises. With operations in the U.S., UK, India, and Dubai, FMI provides data-backed insights and strategic intelligence across 30+ industries and 1200 markets worldwide.

This release was published on openPR.